Traumatic life experiences are associated with alcohol use problems, an association that is likely to be moderated by genetic predisposition. To understand these interactions, we conducted a gene-by-environment genome-wide interaction study (GEWIS) of alcohol use problems in two independent samples, the Army STARRS (STARRS, N = 16 361) and the Yale-Penn (N = 8084) cohorts. Because the two cohorts were assessed using different instruments, we derived separate dimensional alcohol misuse scales and applied a proxy-phenotype study design. In African-American subjects, we identified an interaction of PRKG1 rs1729578 with trauma exposure in the STARRS cohort and replicated its interaction with trauma exposure in the Yale-Penn cohort (discoveryreplication meta-analysis: z = 5.64, P = 1.69 × 10 − 8 ). PRKG1 encodes cyclic GMP-dependent protein kinase 1, which is involved in learning, memory and circadian rhythm regulation. Considering the loci identified in stage-1 that showed same effect directions in stage-2, the gene ontology (GO) enrichment analysis showed several significant results, including calcium-activated potassium channels (GO:0016286; P = 2.30 × 10 − 5 ), cognition (GO:0050890; P = 1.90 × 10 − 6 ), locomotion (GO:0040011; P = 6.70 × 10
INTRODUCTION
Exposure to traumatic life events is associated with a variety of health risk behaviors, including alcohol use disorders (AUDs). 1, 2 The heritability of AUD is~50%. 3 Genome-wide association studies (GWASs) of AUD have identified several risk alleles. 4 Individuals with AUD likely present some complex trait risk mechanisms that are different from those of the general population. 5, 6 A recent phenome-wide analysis demonstrated that AUD risk alleles are associated with a wide range of physical and mental health consequences. 7 The environment also contributes to the predisposition to AUD, moderating the effects of risk alleles. 8 Traumatic events affect genome regulation via different mechanisms; 9, 10 and it should be possible to identify specific genes that interact with traumatic experiences to moderate AUD risk. Previous studies focused on candidate stress-response genes, such as 5-HTTLPR, PER1 and FKBP5, [11] [12] [13] and investigated how the exposure to life trauma interacts with risk alleles in relation to AUD. However, the candidate-gene approach has limited ability to identify the genetic basis of complex traits.
14 Conversely, GWAS of complex traits conducted in large cohorts have identified numerous risk alleles and some of the pathogenic mechanisms underlying genetically complex diseases. Similarly, genome-wide gene-by-environment interaction studies (GEWISs) can be useful in understanding how environmental factors interact with an individual's genetic background to regulate the predisposition to complex traits. However, to date, there have been few published GEWIS. One reason is that large cohorts that could be meta-analyzed are rarely ascertained using compatible criteria, and relevant differences can be present in the assessment of phenotypic outcome and environmental factors. Thus, it is difficult to investigate large cohorts evaluated with homogeneous assessments. Differences in phenotypic assessment can reduce the statistical power of meta-analysis and replication studies, especially for GEWIS, as they are performed using two kinds of phenotypic data with respect to both the outcome and an environmental factor.
Using data from a GWAS of AUD, we observed that risk alleles in ADH1B, one of the best-validated loci for alcohol drinking behaviors, show different associations with Diagnostic and Statistical Manual of Mental Disorders, fourth edition vs Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) AUD criteria. 15 To reduce error related to different phenotypic assessments, we performed a genome-wide gene-by-trauma interaction study considering the proxy-phenotype approach proposed by Rietveld et al. 16 Specifically, we used the cohorts from the Army STARRS (STARRS) Initiative (N = 16 361) for stage-1 and the Yale-Penn sample (N = 8084) for stage-2, which yielded a total sample of 24 445 individuals. To our knowledge, this is the largest GEWIS performed in psychiatric genetics and the first examining risk for alcohol misuse.
MATERIALS AND METHODS

Army STARRS cohorts
Subjects investigated were selected from among the participants in the STARRS Initiative. All subjects gave written informed consent to participate. These procedures were approved by the Human Subjects Committees of all collaborating institutions.
Sample. Two study populations were included in the STARRS Initiative ( Table 1 ). The New Soldier Study includes soldiers at the start of their basic training at one of three Army installations. The Pre-Post Deployment Study is a multiple-wave panel survey that collected baseline data (time 0) from US Army soldiers in three brigade combat teams prior to their deployment to Afghanistan. Detailed information about the design and conduct of STARRS is available in a previous report. 17 Procedures. Phenotypes for STARRS were obtained using a selfadministered questionnaire, which included a computerized version of the Composite International Diagnostic Interview Screening Scales (CIDI-SC). 18 From the CIDI-SC assessment, we extracted information regarding lifetime trauma exposure and alcohol misuse.
Lifetime trauma assessment. Lifetime trauma exposure (that is, exposed vs unexposed) included reporting of any of the following experiences: serious physical assault; sexual assault or rape; witnessing someone being seriously injured or killed; discovering or handling a dead body; a lifethreatening illness or injury; a disaster; any other experience that put the subject at risk of death or serious injury; murder of a close friend or relative; suicide of a close friend or relative; combat death of a close friend or relative; or accidental death of a close friend or relative. Further details on the trauma assessments were reported in our previous study. 19 Alcohol use assessment. For the STARRS cohort, a dimensional measure of alcohol misuse was derived by summing responses to 13 items that assessed frequency and consequences of alcohol use including the array of alcohol misuse symptoms: (1) frequency of drinking; (2) frequency of binge drinking; (3) drinking interfered with responsibility; (4) drinking caused an argument; (5) drinking resulted in someone getting hurt; (6) out of control drinking; (7) arrested due to drinking; (8) worried to not be able to drink; (9) worried about drinking; (10) feel a need to cut down; (11) feel annoyed by people who mention drinking; (12) feel guilty about drinking; and (13) drink first thing in the morning. Respondents rated each symptom on a 5-point frequency scale that ranged from 'never' through 'every or nearly every day'. Supplementary Table 1 summarizes the items related to lifetime trauma exposure and alcohol-related symptoms. We included only subjects who reported having ever consumed an alcoholic drink (that is, alcohol exposed). For Pre-Post Deployment Study subjects, we considered trauma and alcohol information reported at time 0 (within~6 weeks prior to deployment).
Genetics. The New Soldier Study and Pre-Post Deployment Study samples (STARRS1, N = 14 000) underwent genotyping using the Illumina OmniExpress and Exome array (Illumina, San Diego, CA, USA) with additional custom content. An additional 2361 New Soldier Study samples (STARRS2) were genotyped on the Illumina PsychChip array. Methods for genotyping, imputation, ancestry assignment and principal component analysis were described previously. 19, 20 Yale-Penn cohort Sample. The subjects in the Yale-Penn cohort were recruited at five sites in the eastern United States and were previously investigated in genetic studies of substance use disorders and other traits (Table 1) . 4, [21] [22] [23] [24] The institutional review board at each participating site approved the study and we obtained written informed consent from each participant.
Trauma and alcohol use assessment. The Yale-Penn participants were evaluated using the Semi-Structured Assessment for Drug Dependence and Alcoholism, 25, 26 which yields diagnostic and statistical manual of mental disorders, fourth edition and DSM-5 diagnoses of lifetime alcohol and drug dependence, and other major psychiatric traits. Lifetime trauma exposure was defined as previous experience or witnessing of traumatic events including military combat; an assault, rape or kidnapping; seeing someone seriously injured or killed; a flood, earthquake, large fire or other disaster; an airplane crash or serious car accident; a shooting or bombing; or any situation where you feared there was a serious threat to your life or the life of another person. DSM-5 AUD criterion count was used as a dimensional measure based on the 11 DSM diagnostic criteria for AUD. Further details are reported in our previous study. 15 In the analysis, we included only subjects who reported having ever consumed alcohol (that is, were alcohol exposed).
Genetics. The Illumina HumanOmni1-Quad v1.0 microarray (Illumina) was used to genotype 5546 subjects (Yale-Penn1) at the Center for Inherited Disease Research or the Yale Center for Genome Analysis; and the Illumina HumanCoreExome array was used to genotype 2538 additional subjects at the Gelernter Lab at Yale (Yale-Penn2). Genotyping, Imputation, ancestry assignment and principal component analysis are described in our previous articles.
4,21-24
Data analysis A proxy-phenotype analysis was conducted considering the STARRS cohorts (STARRS1 and STARRS2), as the discovery sample (stage-1), and the Yale-Penn cohorts (Yale-Penn1 and Yale-Penn2), as the replication sample (stage-2). Proxy-phenotype analysis is a two-stage research strategy proposed by Rietveld and colleagues. 15 In the first stage, a proxy phenotype (that is, alcohol misuse) was used to identify a relatively small set of single-nucleotide polymorphisms (SNPs) considering a suggestive statistical significance threshold (that is, Po 5 × 10 − 5 ). In the second stage, this set of candidate SNPs was tested in an independent sample with respect to the phenotype of interest (that is, AUD) at a significance threshold corrected for the number of proxy-associated SNPs. Consistent with the National Institute of Mental Health's Research Domain Criteria initiative, [27] [28] [29] we considered two-dimensional measures derived from symptom scales based on self-report information: an alcohol misuse score in the STARRS cohorts and a DSM-5 AUD criterion count in the Yale-Penn cohorts. Dichotomous trauma exposure was considered as an interactive factor, because it was available in both cohorts. A genome-wide gene-bytrauma interaction analysis was conducted in the STARRS cohorts (stage-1). Considering linkage disequilibrium-independent variants with Po5 × 10 − 5 in the STARRS analysis, a replication analysis was performed in the Yale-Penn cohorts (stage-2). Independent variants were defined as 4500 kb distant and with r 2 o0.2. SNPs that survived a Bonferroni correction that accounted for the number of independent loci were considered a replication. The statistical power of our GEWIS was calculated using QUANTO software (available at http://biostats.usc.edu/Quanto.html).
In the STARRS sample, we have 92.7% statistical power to detect a moderate G × E effect (β G × E = 0.7) at significance level Po5 × 10 − 5 for alleles with frequency ⩾ 5%. In the Yale-Penn sample, we have 88% statistical power to detect a moderate G × E effect (β G × E = 0.7) at significance level Po5 × 10 − 4 for alleles with frequency ⩾ 5%. Plink 1.9 (ref. 30 ) was used to conduct the analysis in the STARRS cohort, and the interaction test was based on comparing the difference between regression coefficients in the trauma-exposed subjects vs the traumaunexposed subjects. Because the Yale-Penn cohorts include related individuals, we performed the interaction analysis using the R package GWAF 31 to fit a generalized estimating equations model to adjust for correlations among related individuals. To verify that no important differences between the two methods were present, we tested the GWAF package and Plink 1.9 in a cohort of unrelated subjects and observed negligible differences due to number approximations. In both analyses, we included SNPs with minor allele frequency ⩾ 5% and high imputation quality (Info ⩾ 0.8). Before being entered into the analysis, alcohol misuse dimensional scales (that is, alcohol misuse count and DSM-5 AUD criterion count) were adjusted for age, sex and the top-10 ancestry principal components, and then normalized using appropriate Box-Cox power transformations. In every analysis, the samples were stratified by genotyping array and ancestry, and the results were combined by metaanalysis using the program METAL. 32 Functional annotation of the identified loci was conducted using HaploReg v4.1. 33 Finally, we evaluated whether the number of loci that showed the same effect directions in the STARRS and the Yale-Penn cohorts was significantly different from chance, by conducting a permutation analysis; and then performed a gene ontology (GO)-enrichment analysis on the basis of the direction-replicated loci using DAVID 6.8 beta version (released May 2016; available at https://david-d.ncifcrf.gov/home.jsp). Fisher's exact tests and Bonferroni multiple testing corrections were applied in the GO-enrichment analysis. We also used WebGestalt 34 (available at http:// www.webgestalt.org/) to conduct an enrichment analysis for KEGG pathways using hypergeometric statistical method and Benjamini-Hochberg multiple test adjustment with significance level set at 0.05. Table 1 reports the characteristics of the cohorts included in our GEWIS. Both STARRS and Yale-Penn samples include subjects genotyped with different platforms. Accordingly, we stratified the samples according to their genotyping platform and used a metaanalytic approach to integrate the results for stage-1 (STARRS1 and STARRS2) and stage-2 (Yale-Penn1 and Yale-Penn2) cohorts. Within each study population (STARRS and Yale-Penn), the cohorts have similar characteristics (age, sex, ancestry and trauma exposure), except for sex between the STARRS cohorts (STARRS1 women = 12%; STARRS2 women = 22%). Considering the differences between the two study populations (STARRS vs Yale-Penn), the STARRS cohorts are mainly constituted by young Europeandescent subjects, whereas the Yale-Penn cohorts mainly consist of older participants with both sexes and ancestries (European and African) almost equally represented. No Hispanic-American group is included in the Yale-Penn cohorts. Lifetime trauma exposure is slightly higher in the STARRS cohorts than that observed in the Yale-Penn cohorts (77 vs 65%).
RESULTS
In the first stage, the genome-wide gene-by-trauma interaction analysis of alcohol misuse showed negligible inflation or deflation in the ancestry-stratified investigations of the STARRS cohorts (Supplementary Table 2 ). This confirmed that no systematic bias affected our GEWIS. G × E analysis can be biased by interactions among predictors and this can be hardly detected in a candidategene study. 35 In a GEWIS, a systematic bias in the G × E model would have caused inflation in the distribution of the test statistics.
There was no genome-wide significant result in the ancestryspecific or the trans-population meta-analyses. Considering Po 5 × 10 − 5 as the significance threshold for follow-up in the second stage of the proxy-phenotype analysis, we identified 68, 49 and 45 independent loci in African-specific, European-specific and trans-population meta-analyses, respectively (Supplementary Table 3 ). In African-American (AA) subjects, we identified an interaction of PRKG1 rs1729578 with trauma exposure in the STARRS cohort and replicated its interaction with trauma exposure in the Yale-Penn cohort (discovery-replication meta-analysis: z = 5.64, P = 1.69 × 10 − 8 ; STARRS AA: z = 4.46, P = 8.09 × 10 − 6 ; Yale-Penn AA: z = 3.62, P = 2.98 × 10 − 4 ). Table 2 shows the details of the association of rs1729578 with alcohol misuse in traumaexposed and -unexposed subjects, and its interaction with trauma exposure in relation to alcohol misuse. In the meta-analysis of the discovery (stage-1) and replication (stage-2) AA cohorts (N = 6744), rs1729578 showed a genome-wide significant interaction with trauma exposure in relation to alcohol misuse (z = 5.64, P = 1.69 × 10
; Figure 1 ). Rs1729578*C allele was positively associated with alcohol misuse in trauma-exposed subjects (z = 4.27, P = 1.96 × 10 − 5 ); and was negatively associated in traumaunexposed subjects (z = − 5.29, P = 1.21 × 10 − 7 ). No significant replication was observed in the European-American (EA) or transpopulation meta-analysis. The Hispanic-specific meta-analysis could not be included in the second stage because no Hispanic group was available for replication in the Yale-Penn cohorts.
Rs1729578 is located in an intron of PRKG1 (cyclic GMP (cGMP)-dependent protein kinase 1), and in AAs it is in high linkage disequilibrium (r 2 40.8) with other two PRKG1 intronic variants (rs1194520 and rs871995). According to the data provided by the Roadmap Epigenomics Consortium and the ENCODE Project Consortium, 36, 37 rs1729578 is associated with a MIZF motif change; rs1194520 is located in enhancer histone marks (six tissues), DNAse sites (16 tissues), a CFOS protein-bound site, and it is associated with four altered transcription factor motifs (Irf, SETDB1, STAT and YY1). Similarly, rs871995 is located in promoter histone marks (18 tissues), enhancer histone marks (8 tissues), DNAse sites (1 tissue) and is associated with three transcription factor-altered motifs (Foxp1, Hoxa10 and Irf). Details on chromatin-state annotation of the PRKG1 variants are provided in Supplementary Table 4 .
Finally, we verified whether the loci identified in stage-1 had the same effect directions in the stage-2 cohorts. In all of the analyses (African-specific, European-specific and trans-population), we Table 2 . Association of PRKG1 rs1729578*C allele with alcohol-related dimensional scales in subjects of African descent exposed and unexposed to lifetime trauma.
Cohort
Allele Genome-wide gene-by-trauma interaction with alcohol misuse R Polimanti et al observed that the number of stage-1-identified loci with the same effect directions in the stage-2 cohorts was higher than would be expected by chance (Figure 2 ): 42 loci in AAs (P permutation = 0.022); 33 loci in EAs (P permutation = 0.004); and 28 loci in the transpopulation analysis (P permutation = 0.041). Considering these loci with the same direction in both cohorts (Supplementary Table 5 ), we observed significant enrichment for: GO:0016286~small conductance calcium-activated potassium channel activity in AAs; GO:0040011~locomotion in EAs; GO:0050890~cognition; and GO:0042517~positive regulation of tyrosine phosphorylation of Stat3 protein. Details regarding the results of enrichment analysis are reported in Table 3 . The analysis based on KEGG pathways identified several significant enrichments (Supplementary Table 6 ). Calcium signaling pathway (KEGG ID: 04020) was also confirmed by this analysis. Other relevant molecular pathways were as follows: cytokine-cytokine receptor interaction (KEGG ID: 04060); long-term potentiation (KEGG ID: 04720); and insulin signaling pathway (KEGG ID: 04910).
DISCUSSION
To our knowledge, this study, which included 24 445 individuals, is the largest GEWIS in psychiatric genetics, and the first examining risk for alcohol misuse. Because the cohorts investigated were assessed using different instruments and criteria intended to measure similar domains, we applied the proxy-phenotype approach. 16 In AAs, our proxy-phenotype analysis uncovered a variant, rs1729578, identified in the STARRS cohorts and replicated in the Yale-Penn samples. The rs1729578*C allele showed an interaction with trauma exposure in relation to alcohol misuse symptoms. Although it has similar allele frequencies in European-and Africanancestry populations, no effect was observed in the European cohort, possibly due to a different haplotype structure in these groups. 38 In African populations, the variant is in high linkage disequilibrium (r 2 40.8) with other two variants, rs1194520 and rs871995. These SNPs are located in an intron of PRKG1, the gene encoding cGMP-dependent protein kinase 1. Functional annotation from the Roadmap Epigenomics Consortium and the ENCODE Project Consortium indicated that these variants are located in genomic regulatory regions. 36, 37 Specifically, they are located within multiple chromatin marks across different tissues. Previous studies have demonstrated that non-coding variants identified by GWAS are enriched for chromatin modifications. 39 The PRKG1 protein product, cGMP-dependent protein kinase 1, corresponds to both the type I alpha and type I beta isoforms of cGMP- The gene is most strongly expressed in smooth muscle, platelets, cerebellar Purkinje cells, hippocampal neurons and the lateral amygdala. 40, 41 cGMP plays an important role in learning and memory, 42 and a PRKG1 knockout mouse model showed alterations in the cerebellar phospho-proteome that suggests impaired cerebellar long-term depression at Purkinje cell synapses.
43 PRKG1 mutant mice also show differences from wildtype mice in circadian rhythms, sleep and distinct aspects of learning. 44 Mouse models also demonstrate that cGMP-dependent protein kinase 1 in the amygdala is critical for auditory-cued fear memory and long-term potentiation. 45, 46 In vitro studies also show that cGMP-dependent protein kinase 1 isoforms are involved in serotonin transporter regulation. 47 In Drosophila melanogaster, the homolog of the human PRKG1, the well-studied foraging (for) gene encodes a cGMP-dependent protein kinase (PKG). Two for variants have been observed in nature: rover allele (for R ) with high PKG activity and sitter allele (for s ) with low PKG activity. 48 In Drosophila, PKG activity interacts with early life stress in determining adult exploratory and fitness traits. 49, 50 PKG activity seems to control synaptic transmission tolerance to acute stress at the Drosophila larval neuromuscular junction, where inhibition promotes functional protection, whereas activation increases susceptibility to neurotransmission breakdown. 51 A GWAS of post-traumatic stress disorder identified PRKG1 as a risk locus in a military cohort independent from those investigated in the current studies, 52 also supporting the role of PRKG1 in stress-response-related traits in humans.
Finally, our proxy-phenotype analysis demonstrated that the enrichment for loci with same effect direction in stage-1 and stage-2 was unlikely to be due to chance. Investigating these loci, we observed indicative GO enrichments. The enrichment for GO:0016286~small conductance calcium-activated potassium channel activity confirmed previous findings of genome-wide genetic and epigenetic investigations on the role of potassium channels and calcium metabolism in substance use disorders. 21, 22, 53 Both GO:0040011~locomotion and GO:0050890~cognition appear consistent with the role of genes involved in mobility and cognitive functions highlighted by the PRKG1 result. GO:0042517~positive regulation of tyrosine phosphorylation of Stat3 protein suggests that mechanisms related to STAT3 regulation are involved in the trauma response. STAT3 is involved in signal transduction and transcription activation of a wide range of genes in response to cell stimuli, 54 but no studies have yet investigated its involvement in the behavioral stress response. Pathway-based enrichment analysis confirmed the GO result related to the calcium metabolism (calcium signaling pathway, KEGG ID: 04020). Besides this confirmatory result, the most significant pathway enrichment was observed for cytokinecytokine receptor interaction (KEGG ID: 04060). This is a relevant pathway related to immune functions such as inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. Our previous GWAS of PTSD showed a strong overlapping with autoimmune diseases 19 and our current findings confirm the role of immune functions in trauma response.
In conclusion, our study provides the first genome-wide evidence regarding a mechanism by which traumatic life events interact with human genetic variation in relation to alcohol misuse. However, although to our knowledge this is the largest GEWIS performed in psychiatric genetics, our current findings are still limited and further GEWIS with larger sample sizes together with translational studies will be needed to uncover more completely how traumatic experience interacts with the genetic predisposition to modify risk for AUDs. Our main result is the identification of PRKG1 rs1729578 as a risk locus interacting with trauma exposure in determining alcohol misuse. Our study design included different types of trauma within the 'lifetime trauma exposure' category. As certain traumatic experiences may be consequences of the alcohol abuse (for example, individuals who abuse alcohol are more likely to have motor vehicle collisions than those who do not abuse alcohol), further studies are needed to dissect the complex interactive network of alcohol misuse, trauma experience and genetics. Additional experiments are also necessary to understand the molecular mechanisms (for example, epigenetic changes and transcriptional regulation) involved in this interactive process. However, the PRKG1 locus encodes a prospective target for the development of pharmacological treatments for stress-response-related traits. Indeed, an in vivo study has shown that the blockade of a1-adrenergic receptors mitigates stress-disturbed cGMP signaling. 55 Further studies should consider whether pharmacological treatments targeted at the cGMP signaling system are useful to reduce risk behaviors, such as alcohol misuse, in subjects exposed to traumatic events. Other potential targets for future translational investigations of trauma-related psychopathologies include potassium channels, calcium metabolism and STAT3 regulation system.
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